BioLineRx (BLRX) Other Non-Current Liabilities (2021 - 2025)

BioLineRx has reported Other Non-Current Liabilities over the past 5 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $2.2 million for Q4 2025, up 28.56% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (up 28.56% YoY), and the annual figure for FY2025 was $2.2 million, up 28.56%.
  • Other Non-Current Liabilities for Q4 2025 was $2.2 million at BioLineRx, up from $1.7 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for BLRX hit a ceiling of $11.9 million in Q4 2023 and a floor of $1.7 million in Q4 2024.
  • Median Other Non-Current Liabilities over the past 5 years was $2.2 million (2025), compared with a mean of $4.4 million.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 164.63% in 2023 and later plummeted 85.83% in 2024.
  • BioLineRx's Other Non-Current Liabilities stood at $1.9 million in 2021, then soared by 142.55% to $4.5 million in 2022, then soared by 164.63% to $11.9 million in 2023, then plummeted by 85.83% to $1.7 million in 2024, then grew by 28.56% to $2.2 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $2.2 million (Q4 2025), $1.7 million (Q4 2024), and $11.9 million (Q4 2023) per Business Quant data.